Company intelligence / Profile preview
RAPT Therapeutics
South San Francisco, California, United Statesrapt.com ↗
- Ownership
- Public · RAPT
- Development stage
- Other
01
Overview
RAPT Therapeutics is advancing RPT904, a novel monoclonal antibody targeting IgE for food allergy, with a Phase 2b trial planned for the second half of 2025. The company recently secured significant funding through a $150 million private placement to advance its R&D pipeline.[7][8]
- Therapeutic areas
- OncologyImmunologyDermatology
- Modalities
- Small moleculesBiologics (monoclonal antibodies)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Jemincare (license agreement for RPT904 worth up to $672.5M in milestone payments plus royalties)
Beyond the preview
Go deeper on RAPT Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RAPT Therapeutics.